Dr. Leticia Varella (Letícia Varella) discussed systemic therapy for ER+ cancers during the Early #BreastCancer Session at the #HarvardBreastCancerCourse.

What an honor to have Dr. Aleix Prat deliver the Schlager lecture at the Harvard Breast course! An incredible overview of the complexities of HER2 biology and the role of HER2DX! Aleix Prat #PrecisionOncology Dana-Farber’s Breast Oncology Center

Thanks, Paolo, for the acknowledgment ! 🙏🏻😊

📘Systemic Therapy in Breast Cancer ASCO Educational Book ✅An excellent review with summary tables of practice changing trials 👉doi.org/10.1200/EDBK_4… Journal of Clinical Oncology JCO Precision Oncology JCO Oncology Practice The ASCO Post OncoAlert #cancer #oncology #breast #MedX

Systemic Therapy in Breast Cancer Erman Akkus ASCO Chiara Corti Hemali Batra-Sharma, MD Max Kelsten Rebecca Shatsky, MD William Gradishar, MD oncodaily.com/insight/106222… #Cancer #ASCO #BCSM #ClinicalTrials #OncoDaily #Oncology

Easier access to our paper on current standards and future goals for systemic therapy in breast cancer. ascopubs.org/doi/full/10.12… #bcsm Chiara Corti William Gradishar, MD Hemali Batra-Sharma, MD UC San Diego Health Moores Cancer Center ASCO Journal of Clinical Oncology Dana-Farber

Here's the most recent #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (July 15th-21st, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Over 1,900 downloads in less than a week for our educational chapter on systemic therapy in #breastcancer. Thank you! Easy access here: ascopubs.org/doi/10.1200/ED… #teamwork #bcsm William Gradishar, MD Rebecca Shatsky, MD Hemali Batra-Sharma, MD UC San Diego Health Moores Cancer Center ASCO Journal of Clinical Oncology Dana-Farber’s Breast Oncology Center

For #TrialTuesday, .Sara Tolaney Dana-Farber leads Alliance for Clinical Trials in Oncology A012103 to compare the effect of pembrolizumab to observation in pts w/triple-negative #breastcancer who had a pathologic complete response after chemotherapy plus pembrolizumab - bit.ly/Alliance-A0121… #NCI #NCTN

Great to see respect & friendship between U.S. & Italian women's artistic gym teams, who won the gold & silver medals, respectively, at #Paris2024. Incredible comeback for #SimoneBiles & a historic day for Italy, winning first #Olympic medal in this category in almost a century.

“OPEN FOR BUSINESS” - Authors are increasingly paying to publish their papers open access. But is it fair or sustainable? science.org/content/articl…

If a place is as good as the people u know in it, I understand why Dana-Farber’s Breast Oncology Center is so special. My 1st yr here flew by, and I couldn't be more grateful for all I've learnt & the genuinely committed & compassionate people I've met. Looking forward to many more yrs to come! 🥹

Thanks, Busem! 🙏🏻🥹

We heard from Dana-Farber’s Chief Medical Officer, Dr. Craig Bunnell, on the importance of philanthropy: “In order to get grants, scientists need to demonstrate a track record. Young scientists, the ones who are starting out, don’t have a track record. That’s where philanthropy

Check out our ASCO Daily News editorial “IMpassion132: Learning From Immunotherapy’s Failures in Early Relapsing Triple-Negative Breast Cancer” at dailynews.ascopubs.org/do/impassion13… Chiara Corti Dana-Farber’s Breast Oncology Center

IMpassion132, a phase 3 trial of chemo + ICI for early relapsing triple-negative #BreastCancer, was a negative study that provided informative results for an understudied population. Chiara Corti & Ilana Schlam dig into the results for #ASCODailyNews: dailynews.ascopubs.org/do/impassion13… #bcsm

The citation black market: schemes selling fake references alarm scientists “The scientists bought the citations for US$300 from a firm that seems to sell bogus citations in bulk. This confirms the existence of a black market for faked references […]” nature.com/articles/d4158…

Meet Dr. Thomas Grinda (Thomas Grinda), an Advanced Fellow in the Breast Oncology Center Dana-Farber! Our fellowship provides comprehensive clinical & investigative training to those planning a career in research in an academic setting in the care & management of #BreastCancer.

Register today for the 2024 DF/HCC Breast Cancer Program Research Retreat titled AI-Driven Cancer Solutions: From Basic Science to Standard of Care in #BreastCancer & Beyond. 🗓️Fri Sept 20th, 12:00-6:00pm 📍 Starr Center, MGH, 185 Cambridge St, Boston dfhcc.harvard.edu/events/breast-…

Hot off the press: Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States - by Sara Tolaney et al. esmoopen.com/article/S2059-…